Mometasone furoate is under clinical development by Lyra Therapeutics and currently in Phase III for Rhinosinusitis. According to GlobalData, Phase III drugs for Rhinosinusitis have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Mometasone furoate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mometasone furoate overview
LYR-210 is under development for the treatment of chronic rhinosinusitis in surgically-naive patients. The drug candidate is a long acting formulation of steroid mometasone furoate. It is developed based on the XTreo transmucosal therapeutic system and administered through transmucosal and nasal routes as implant. The technology provides the delivery of drug through the polymeric matrix, to contour to the treatment area (into the sinonasal tissues) and adapt to inflamed remodeling tissue. The drug candidate acts by targeting the glucocorticoid receptor.
Lyra Therapeutics overview
Lyra Therapeutics specializes in developing medicines to treat ear, nose and throat (ENT) diseases. The company is headquartered in United States.
For a complete picture of Mometasone furoate’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
